Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Cancer. 2016 Aug 15;122(22):3456–3463. doi: 10.1002/cncr.30270

Figure 1.

Figure 1

Waterfall plot depicting best percentage change from baseline in tumor size for individual patients in the reduced-dose erlotinib group. Twenty out of 26 patients had a maximum response of over 30%, leading to an ORR of 77% for reduced-dose erlotinib.